Lundbeck Articles
Lundbeck launches Circadin in eastern Europe
3 November 2008
Finland's Biotie to acquire elbion GmbH
3 November 2008
Teva's Azilect meets all endpoints in ADAGIO trial
8 September 2008
Lundbeck profit down 52% on Flurizan failure
1 September 2008
Myriad/Lundbeck drop Ph III AD drug Flurizan
7 July 2008
Lundbeck
9 June 2008
Lundbeck buys drug rights for up to $350M
2 June 2008
Tokyo stocks to May 12, 2008
19 May 2008
Lundbeck launches melatonin sleep aid
19 May 2008
Lundbeck appoints Ulf Wiinberg as CEO
5 May 2008
Forest Labs swings back to profit in fiscal 1st-qtr
21 April 2008
Gilead recruits regional general managers
7 April 2008
Lundbeck's EPS up 65%; shares fall on CEO exit
17 March 2008
H Lundbeck CEO Claus Braestrup resigns
10 March 2008
Wyeth and Solvay end bifeprunox accord
10 March 2008
Pharma majors enter CSN experimental medicines consortium
28 January 2008
Lexapro and Namenda help Forest's income for fiscal 3rd-qtr soar 21%, beating estimates
21 January 2008
Japan stock market week to Nov 14
7 January 2008
Lundbeck's 3rd-qtr net profit soars 67%
3 December 2007
Danish companies agree siramesine deal
15 October 2007
Patent expiries will reduce bipolar drug market $400M
1 October 2007
Japan stock market week to September 10, 2007
17 September 2007
US Apeals Court upholds Lexapro patent decision
10 September 2007
H Lundbeck and Takeda enter mood drug alliance
10 September 2007
Lundbeck's 2nd-qtr 2007 revenue increases 19%
3 September 2007
SSRIs lower BMD in men and women
2 July 2007
Lundbeck drops 9% as stroke drug fails Ph III
11 June 2007
Bifeprunox prolongs time to deterioration
4 June 2007
Anders Goetzche joins H Lundbeck
21 May 2007
Bifeprunox shows good weight and lipid profile
9 April 2007
Merck & Co/Lundbeck terminate gaboxadol
9 April 2007
Pressure on Lundbeck to tie-up or buy in
9 April 2007
H Lundbeck's profit drops 30% for 2006
26 March 2007
Cipralex approved for OCD in Europe
29 January 2007
Patent expiries will stem growth of antidepressants market
18 December 2006
Biotie licenses nalmefene to H Lundbeck
4 December 2006
H Lundbeck's 3rd-qtr net profit up 3%
27 November 2006
LifeCycle Pharma flotation over-subscribed six-fold
20 November 2006
Merck & Co/Lundbeck delay gabodaxol filing
23 October 2006
H Lundbeck's escitalopram is effective in OCD, says study
25 September 2006
Ebixa effective against AD behavioral symptoms
11 September 2006
Strong data for Teva/Lundbeck's Azilect as adjunct
11 September 2006
Teva's Azilect approved for early PD in Canada
28 August 2006
H Lundbeck' 2nd-qtr profits fall 69%
28 August 2006
Cymbalta: less impact on sex than Lexapro
29 May 2006
H Lundbeck's 1st-qtr 2006 profit drops 29%
22 May 2006
Strong data for H Lundbeck's Ebixa in AD
1 May 2006
H Lundbeck's 2005 net profits down 6%
27 March 2006
Lundbeck's Ebixa sees good long-term performance
16 January 2006
PAION and Lundbeck in stroke alliance
18 July 2005
Cephalon/Lundbeck terminate PD drug trial
23 May 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
Sweden's Biovitrum acquires Cambridge Biotechnology
28 March 2005
Encouraging data for Lundbeck's Ebixa in AD
21 March 2005
UK NICE seeks to curb Alzheimer's drugs
7 March 2005
Teva/Lundbeck's Azilect cleared for PD in EU
28 February 2005
Teva's Azilect gets first approval in Israel
10 January 2005
Expanded use of Namenda on track
22 November 2004
Forest pursues new use for Lexapro
6 September 2004
Lundbeck net up 46%
23 August 2004
French drug evaluation group starts work
16 August 2004
Merz' Axura shows benefits in AD
12 July 2004
FDA approvable letter for Teva's Agilect
12 July 2004
Lundbeck/Merck & Co extend gaboxadol deal
5 July 2004
Letter from the Editor
28 June 2004
Lundbeck's Cipralex as effective as rival drug
21 June 2004
Ovation acquires CNS drug from Lundbeck
21 June 2004
Solvay's bifeprunox to see peak sales of $1B
14 June 2004
Cipralex demonstrates superiority in trials
7 June 2004
Lexapro as effective as Paxil for GAD
22 March 2004
Merz
1 March 2004
Merck KGaA
1 March 2004
Forest to seek wider approval of Namenda for Alzheimer's disease
19 January 2004
Lexapro cleared for new use by FDA
5 January 2004
Positive new data for Forest's Lexapro
22 December 2003
UK drug regulation is flawed, says charity
22 December 2003
Lundbeck issues profit warning; shares slump on antidepressant woes
10 November 2003
Rasagiline reduces "off" time in PD
27 October 2003
Teva's rasagiline filed in EU as PD therapy
20 October 2003
Forest's Namenda on track for US approval
6 October 2003
Lundbeck names Claus Braestrup as CEO
29 September 2003
Forest/Lundbeck file suit against IVAX
29 September 2003
lNeuroNova AB and H Lundbeck in collaboration
22 September 2003
Teva seeks US approval of rasagiline for PD
15 September 2003
Solvay and Lundbeck move bifeprunox into Ph III
15 September 2003
IVAX applies to FDA for generic Lexapro
18 August 2003
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
